Meloxicam

Overview

Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is available in oral, transdermal, and intravenous formulations. It is a preferential COX-2 inhibitor, purportedly reducing the risk of adverse gastrointestinal tract effects, however, this is a topic of controversy.

Indication

Meloxicam is indicated for the symptomatic treatment of arthritis and osteoarthritis. In addition, it is indicated for the pauciarticular and polyarticular course of Juvenile Rheumatoid Arthritis (JRA) in patients aged 2 years old or above. Off-label uses include the treatment of dental or post-surgical pain. In addition to the above, meloxicam has also been studied in the treatment of neuropathic pain. Meloxicam, in combination with bupivacaine, is indicated for postsurgical analgesia in adult patients for up to 72 hours following foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.

Associated Conditions

Dental Pain
Neuropathic Pain
Osteoarthritis (OA)
Pain, Inflammatory
Pauciarticular juvenile rheumatoid arthritis
Polyarticular juvenile rheumatoid arthritis, chronic or unspecified
Postoperative pain
Rheumatoid Arthritis

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Efficacy and Safety of Intravenous Meloxicam in Subjects With Moderate-to-severe Pain Following Abdominal Surgery	2025/04/01	NCT06904248	Phase 3	Completed	Yangtze River Pharmaceutical Group Co., Ltd.
Meloxicam Versus Ibuprofen for Pain Control After Third Molar Exodontia in Adult Patients	2024/11/25	NCT06704113	Phase 4	Not yet recruiting	Universidad Austral de Chile
Efficacy and Safety Study of Meloxicam Nanocrystal Injection for the Treatment of Moderate to Severe Pain	2024/04/23	NCT06379165	Phase 3	Completed	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase II Study of Ovulation in Obese Women	2024/03/12	NCT06306131	Phase 2	Recruiting	InnovaGyn, Inc.
Pre vs Post Block in Total Knee Arthroplasty (TKA)	2023/08/03	NCT05974501	Phase 4	Completed	University of Miami
Efficacy, Safety and Tolerability Study of Meloxicam Injection in Subjects After Abdominal Surgery	2023/07/18	NCT05950152	Phase 2	Not yet recruiting	Beijing Tide Pharmaceutical Co., Ltd
Oral Levonorgestrel Plus Meloxicam, IG-002 Delays Ovulation in Normal Menstruating Women by Seven Days	2023/01/25	NCT05695352	Phase 2	Recruiting	InnovaGyn, Inc.
Safety and Pharmacokinetics of N1539 in Children 2 to <17 Years of Age Following Surgery	2022/04/07	NCT05315479	Phase 4	Terminated	Baudax Bio
Meloxicam for Pain Management After Total Joint Arthroplasty (TJA)	2022/03/22	NCT05291598	Phase 3	Completed	University of Miami
Effectiveness of Premedication on the Success Rate of Inferior Alveolar Nerve Block	2021/10/28	NCT05097768	Not Applicable	Completed	Alfarabi Colleges

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
Meloxicam	Exelan Pharmaceuticals Inc.	76282-153	ORAL	15 mg in 1 1	2/17/2023
Meloxicam	Carlsbad Technology, Inc.	61442-126	ORAL	7.5 mg in 1 1	2/17/2023
Meloxicam	STERLING KNIGHT PHARMACEUTICALS, LLC	69336-102	ORAL	15 mg in 1 1	12/30/2015
MELOXICAM	Northwind Pharmaceuticals, LLC	51655-571	ORAL	15 mg in 1 1	1/25/2023
MELOXICAM	REMEDYREPACK INC.	70518-1299	ORAL	7.5 mg in 1 1	2/15/2024
MELOXICAM	AiPing Pharmaceutical, Inc	11788-047	ORAL	15 mg in 1 1	10/6/2023
Meloxicam	Belcher Pharmaceuticals,LLC	62250-676	ORAL	15 mg in 1 1	6/30/2015
MELOXICAM	REMEDYREPACK INC.	70518-1630	ORAL	15 mg in 1 1	6/23/2025
Meloxicam	Advanced Rx Pharmacy of Tennessee, LLC	80425-0043	ORAL	7.5 mg in 1 1	11/10/2022
Meloxicam	Dispensing Solutions, Inc.	66336-774	ORAL	15 mg in 1 1	7/3/2013

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
Arrox Tablet 7.5mg	Xepa-Soul Pattinson (Malaysia) Sdn Bhd	SIN14305P	TABLET	7.50mg	1/31/2013
MOBIC TABLET 7.5 mg	BOEHRINGER INGELHEIM PHARMA GMBH & CO KG, Boehringer Ingelheim Hellas Single Member S.A., Rottendorf Pharma GmbH (Ostenfelder)	SIN09554P	TABLET	7.5 mg	11/28/1997
MELOX TABLET 7.5 mg	MEDOCHEMIE LTD	SIN12127P	TABLET	7.5 mg	11/20/2002

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
MELFLAM-7.5 TAB 7.5MG	N/A	CONTROLLED MEDICATIONS LIMITED	N/A	N/A	3/14/2005
NEWSICAM CAP 15MG	N/A	JULIUS CHEN & COMPANY (H.K.) LIMITED	N/A	N/A	2/8/2010
MEDICON CAPSULE 7.5MG	N/A	WELL FAVOURED LIMITED	N/A	N/A	8/7/2014
MOCAM TABLETS 7.5MG	N/A	EUGENPHARM INTERNATIONAL LIMITED	N/A	N/A	10/3/2019

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
MELOXICAM SANDOZ meloxicam 7.5 mg tablet blister pack	288943	Cipla Australia Pty Ltd	Medicine	A	7/12/2017
MELOXICAM VIATRIS meloxicam 7.5 mg tablet blister pack	389282	Helix Pharmaceuticals Pty Ltd	Medicine	A	10/7/2022
GENRX MELOXICAM	181202	Arrotex Pharmaceuticals Pty Ltd	Medicine	A	10/18/2011
MELOXICAM GPPL meloxicam 7.5 mg capsule blister pack	232578	Arrotex Pharmaceuticals Pty Ltd	Medicine	A	9/23/2015
CIP MELOXICAM 7.5 meloxicam 7.5 mg tablet blister pack	298957	Cipla Australia Pty Ltd	Medicine	A	4/4/2018
MELOXIBELL meloxicam 7.5mg tablet blister pack	127413	Generic Health Pty Ltd	Medicine	A	7/31/2007
MELOBIC 15 meloxicam 15 mg tablets blister pack	188883	Arrotex Pharmaceuticals Pty Ltd	Medicine	A	8/28/2012
MOXICAM meloxicam 15 mg tablet blister pack	126215	Alphapharm Pty Ltd	Medicine	A	5/15/2007
AGILOCAM meloxicam 15 mg capsule blister pack	232587	Arrotex Pharmaceuticals Pty Ltd	Medicine	A	9/23/2015
MELOBIC 15 meloxicam 15 mg capsule blister pack	232583	Arrotex Pharmaceuticals Pty Ltd	Medicine	A	9/23/2015

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
MYLAN-MELOXICAM	Mylan Pharmaceuticals ULC	02255995	Tablet - Oral	15 MG	8/11/2004
PHL-MELOXICAM	pharmel inc	02248607	Tablet - Oral	7.5 MG	4/6/2004
ZYNRELEF	Heron Therapeutics, Inc.	02525968	Solution (Extended Release) - Instillation	1.8 MG / 2.3 ML	N/A
ZYNRELEF	Heron Therapeutics, Inc.	02526026	Solution (Extended Release) - Instillation	9 MG / 10.5 ML	N/A
ZYNRELEF	Heron Therapeutics, Inc.	02526034	Solution (Extended Release) - Instillation	12 MG / 14 ML	N/A
AVA-MELOXICAM	avanstra inc	02365545	Tablet - Oral	7.5 MG	11/8/2011
RATIO-MELOXICAM	ratiopharm inc division of teva canada limited	02247889	Tablet - Oral	7.5 MG	11/11/2003
NU-MELOXICAM	nu-pharm inc	02335514	Tablet - Oral	15.0 MG	N/A
TEVA-MELOXICAM	teva canada limited	02258323	Tablet - Oral	15 MG	10/22/2004
PHL-MELOXICAM	pharmel inc	02248608	Tablet - Oral	15 MG	4/6/2004

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
MOVALIS 7,5 mg COMPRIMIDOS	Boehringer Ingelheim International Gmbh	61075	COMPRIMIDO	Medicamento Sujeto A Prescripción Médica	Commercialized
MELOXICAM NORMON 7,5 mg COMPRIMIDOS EFG	Laboratorios Normon S.A.	69365	COMPRIMIDO	Medicamento Sujeto A Prescripción Médica	Commercialized
MOVALIS 15 mg/1,5 ml SOLUCION INYECTABLE	Boehringer Ingelheim Espana S.A.	64313	SOLUCIÓN INYECTABLE	Medicamento Sujeto A Prescripción Médica	Not Commercialized
MELOXICAM STADA 7.5 mg COMPRIMIDOS EFG	Laboratorio Stada S.L.	66399	COMPRIMIDO	Medicamento Sujeto A Prescripción Médica	Commercialized
MELOXICAM UR 15 mg COMPRIMIDOS EFG	Aristo Pharma Iberia S.L.	67384	COMPRIMIDO	Medicamento Sujeto A Prescripción Médica	Not Commercialized
MELOXICAM CINFA 15 mg COMPRIMIDOS EFG	Laboratorios Cinfa S.A.	69094	COMPRIMIDO	Medicamento Sujeto A Prescripción Médica	Commercialized
MELOXICAM PENSA 7,5 mg COMPRIMIDOS EFG	Towa Pharmaceutical S.A.	68843	COMPRIMIDO	Medicamento Sujeto A Prescripción Médica	Commercialized
MELOZALTAN 15 MG COMPRIMIDOS EFG	Zaltanpharma Laboratorios S.L.	68797	COMPRIMIDO	Medicamento Sujeto A Prescripción Médica	Not Commercialized
MELOXICAM MYLAN 15 mg COMPRIMIDOS EFG	Mylan Pharmaceuticals S.L.	66410	COMPRIMIDO	Medicamento Sujeto A Prescripción Médica	Commercialized
MELOXICAM NORMON 15 mg COMPRIMIDOS EFG	Laboratorios Normon S.A.	69366	COMPRIMIDO	Medicamento Sujeto A Prescripción Médica	Commercialized

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

FDA Approves XIFYRM Injectable Meloxicam for Moderate-to-Severe Pain Management

3 months ago

The FDA has approved XIFYRM (meloxicam injection), a once-daily intravenous NSAID formulation for managing moderate-to-severe pain in adults.

FDA Approves Qamzova: China-Developed Long-Acting Injectable Painkiller to Combat Opioid Crisis

3 months ago

• Qamzova, developed by Nanjing-based Delova Biotech, has received FDA approval as the world's first long-acting injectable NSAID analgesic, providing 24-hour pain relief with a single daily injection. • The meloxicam-based medication offers a safer alternative for moderate-to-severe pain management, potentially reducing dependency on addictive opioids like fentanyl that have fueled the US overdose epidemic. • This approval represents a significant milestone for China's pharmaceutical industry, demonstrating the country's growing capabilities in innovative drug development and international market penetration.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access